The Type 2 Diabetes Market size was estimated at USD 35.78 billion in 2023 and is projected to reach USD 69.55 billion by 2032 and grow at a CAGR of 7.69% over the forecast period 2024-2032.
This report emphasizes the prevalence and incidence of type 2 diabetes, focusing on regional discrepancies and increasing global disease burden. The research reflects prescription trends, highlighting the uptake of insulin and non-insulin therapy, as well as new treatment breakthroughs. It also delves into the expanding use of diabetes management through medical devices like continuous glucose monitors and insulin pumps and their potential to enhance patient outcomes. The report also examines disease progression and complications, discussing how early intervention and lifestyle change affect long-term health. Additionally, it evaluates the most recent clinical trials and pipeline advancements, with a focus on new drug formulations and customized treatment strategies. Patient awareness and lifestyle trends are also examined, with the increased demand for digital health solutions, dietary management programs, and prevention care strategies noted.
To Get more information on Type 2 Diabetes Market - Request Free Sample Report
Drivers
The growth of the Type 2 Diabetes market is driven by increasing diabetes prevalence, advancements in treatment options, and rising awareness about disease management.
As per the International Diabetes Federation (IDF), 537 million adults had diabetes in 2021, and this is projected to increase considerably. The use of new drug classes like GLP-1 receptor agonists (e.g., Ozempic) and SGLT2 inhibitors (e.g., Jardiance) has revolutionized treatment outcomes by providing benefits beyond glucose control, such as cardiovascular and renal protection. Moreover, advances in continuous glucose monitoring (CGM) systems and insulin delivery devices have improved patient compliance and glycemic control. The rising trend of obesity—a significant risk factor for Type 2 Diabetes—has also driven demand further, with more than 1 billion individuals globally designated as obese. Government and private programs, including the CDC's National Diabetes Prevention Program (DPP), are designed to enhance early detection and disease management. The increasing uptake of telemedicine and digital health technologies has also driven market growth by enhancing patient access to diabetes treatment, particularly in underserved communities. The ongoing R&D activities for new therapeutics, such as dual agonists and stem cell therapy, also favor the long-term growth of the market.
Restraints
The Type 2 Diabetes market faces significant restraints, including high treatment costs, limited access to advanced therapies, and concerns regarding medication side effects.
The expense of GLP-1 receptor agonists, like Ozempic and Trulicity, is prohibitive to most patients without full insurance coverage. The price of insulin has also been an issue, with research indicating that more than 25% of insulin users in the United States ration their medication because of the cost. Also, side effects of newer diabetes drugs, including gastrointestinal distress, ketoacidosis (SGLT2 inhibitors), and pancreatitis (GLP-1 agonists), restrict patient compliance. Patient unwillingness to use injectable therapies is another significant restraint, causing delayed switching to insulin or GLP-1 receptor agonists. Regulatory barriers also affect the market, as rigorous FDA and EMA approval procedures slow the introduction of new drugs. Additionally, ignorance and early diagnosis in most poor areas limit timely access to therapy, resulting in increased levels of associated complications like diabetic neuropathy and kidney disease. These issues provide barriers to maximum diabetes control and influence total market growth.
Opportunities
The development of personalized medicine, the expansion of digital diabetes management solutions, and increasing biosimilar adoption.
Personalized medicine, fueled by genetic studies and AI-driven predictive analytics, enables tailored treatment strategies based on unique patient profiles. This has enabled innovation such as dual GLP-1/GIP receptor agonists (e.g., Tirzepatide), which have demonstrated superior efficacy over current therapies. Increasing adoption of digital health technologies, including CGMs, AI-driven insulin dose advisors, and telemedicine platforms, offers a potential for enhancing real-time glucose monitoring and medication compliance. The launch of oral semaglutide (Rybelsus) provides a needle-free option, appealing to patients who are resistant to injectables. The expanding biosimilars market is also a significant opportunity, with biosimilar insulins such as Semglee providing affordable substitutes for high-priced branded insulins. Moreover, rising government interest in diabetes prevention programs and lifestyle interventions, including the WHO's Global Diabetes Compact, is fueling awareness and early diagnosis, creating new opportunities for preventive care. Increased use of AI in drug discovery even makes next-generation diabetes drugs emerge faster, securing market growth over the long term.
Challenges
low adherence to long-term treatment, lack of patient education, and the growing burden of diabetes complications.
Research indicates that more than 50% of diabetic patients do not follow recommended medications because of cost, adverse effects, and complicated dosing schedules. Despite the efficacy of available treatments, lack of disease progression awareness by patients results in delayed interventions and increased rates of complications. Diabetes-related complications like diabetic neuropathy, cardiovascular illnesses, and kidney failure are responsible for the growing burden on health systems, accelerating hospitalization and mortality. Yet another important challenge is physician resistance to the use of newer therapies, with most medical practitioners continuing to use older, more hypoglycemic-prone agents such as sulfonylureas. Even more significant issues are health disparities and unequal access to care, particularly in lower-income groups where patients may be without insurance or have to wait for extended periods for specialist evaluation. The increasing incidence of drug resistance, especially to insulin and oral antidiabetics, adds to the complexity of disease management. These issues can be addressed by improving patient education, access to low-cost therapies, and creation of less complicated yet more efficient treatment regimens.
By Drug Class
In 2023, the segment of insulin had the largest market share in the Type 2 Diabetes market with 32.5% share of the overall revenue. It is because there is a strong prevalence of patients who are dependent on insulin, higher use of basal and ultra-rapid insulin, and increasing uncontrolled burden of diabetes due to insulin treatment. Furthermore, the improvement in insulin delivery equipment like smart insulin pens and insulin pumps has facilitated patient compliance more, leading the market growth forward.
The segment of SGLT2 inhibitors is the most rapidly growing, with growth fueled by growing use of oral antidiabetic drugs that provide cardiovascular and renal protection on top of glucose control. Doctors are now more frequently prescribing SGLT2 inhibitors because of their effectiveness in lowering the risk of heart failure and kidney disease in Type 2 Diabetes patients.
By Route of Administration
Oral segment generated the highest revenue contribution of 55.4% in 2023 owing to the prevalence of first-line oral antidiabetic drugs like metformin, SGLT2 inhibitors, and DPP-4 inhibitors. Patient preference is influenced by convenience, ease of use, and lesser requirements for injections leading to it being the most preferred mode of therapy for Type 2 Diabetes management.
The subcutaneous route is the most rapidly growing, since it is used more and more with GLP-1 receptor agonists and insulin therapy. Increasing demand for GLP-1 receptor agonists, which have substantial weight reduction advantages in addition to control of blood glucose, has led to this growth. The development of long-acting injectable products has enhanced patient compliance, leading to increased market growth as well.
By Distribution Channel
The retail pharmacies segment led the market with a 70.3% revenue share in 2023, as retail pharmacies are still the most convenient point of purchase for diabetes drugs. Most patients use retail pharmacies because they are convenient, have prescription refills, and pharmacist consultation services, especially in developed markets with established pharmacy networks.
The fastest-growing segment is the online and specialty pharmacies segment, driven by the growing trend toward digital health, mail-ordering prescriptions, and distribution of specialty drugs. Telemedicine and online pharmacy platforms have made it convenient for patients to obtain diabetes drugs, especially in remote locations, sustaining the growth of this segment.
North America led the Type 2 Diabetes market in 2023 with a revenue share of 37.9%, fueled by the prevalence of diabetes, developed healthcare infrastructure, and high uptake of cutting-edge therapy solutions. The region is aided by high availability of insulin therapies, GLP-1 receptor agonists, and SGLT2 inhibitors due to positive reimbursement policies. Availability of prominent pharmaceutical players, research being carried out, and government policies focusing on awareness generation and early diagnosis of diabetes are also among the factors boosting the market's growth. Also, the rising usage of digital health solutions, such as continuous glucose monitoring systems and telemedicine-based diabetes management, has boosted the position of North America in the market.
The Asia-Pacific market is the region with the fastest growth rate, fueled by increasing prevalence of diabetes, improving healthcare spending, and rising awareness about advanced treatments. China and India are witnessing a swift increase in the incidence of Type 2 Diabetes because of changing lifestyles, urbanization, and eating habits. The growing population of the middle class and enhancing access to healthcare centers are further driving market growth. Moreover, the increasing usage of affordable generic medicines, diabetes management programs sponsored by the government, and rising demand for oral anti-diabetic drugs are supporting the region's high growth rate. The movement towards online pharmacies and digital healthcare is also serving to open up market access in Asia-Pacific.
Get Customized Report as per Your Business Requirement - Enquiry Now
Amgen Inc.
AstraZeneca PLC – Farxiga, Xigduo XR, Bydureon
Boehringer Ingelheim International GmbH – Jardiance, Glyxambi
Daiichi Sankyo Co. Ltd – Nesina, Kazano
Eli Lilly and Co. – Jardiance, Trulicity, Efsitora (experimental)
Merck & Co. Inc – Januvia, Steglatro
Novartis AG – Galvus, Galvusmet
Novo Nordisk AS – NovoLog, Levemir, Tresiba, Fiasp, Ozempic, Rybelsus
Sanofi SA – Lantus, Toujeo, Apidra, Soliqua
Takeda Pharmaceutical Co. Ltd – Actos, Nesina, Kazano
In March 2025, Sun Pharmaceutical announced its plans to launch Utreglutide, an experimental anti-obesity and Type 2 Diabetes drug, within the next four to five years, according to Managing Director Dilip Shanghvi. The company joined other Indian drugmakers in targeting the booming USD 150 billion weight-loss drug market expected by the end of the decade.
In Feb 2025, Tandem Diabetes Care received FDA clearance for its Control-IQ+ automated insulin delivery (AID) technology for Type 2 Diabetes in adults (18+ years). Previously approved for Type 1 Diabetes, the updated algorithm accommodates expanded weight and insulin ranges. The U.S. launch is expected in March 2025.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 35.78 billion |
| Market Size by 2032 | USD 69.55 billion |
| CAGR | CAGR of 7.69% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Drug Class [Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors, Others] • By Route of Administration [Oral, Subcutaneous, Intravenous] • By Distribution Channel [Retail Pharmacies, Hospital Pharmacies, Other] |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Karl Storz, Boston Scientific Corporation, Olympus America, Endo Pharmaceuticals Inc., biolitec AG, Medifocus, Cook Medical, Teleflex Incorporated, Urotronic, Coloplast Corp, Richard Wolf GmbH, PROCEPT BioRobotics Corporation. |
Ans: The Type 2 Diabetes market is projected to grow at a CAGR of 7.69% during the forecast period.
Ans: By 2032, the Type 2 Diabetes market is expected to reach USD 69.55 billion, up from USD 35.78 billion in 2023.
Ans: The growth of the Type 2 Diabetes market is driven by increasing diabetes prevalence, advancements in treatment options, and rising awareness about disease management.
Ans: The Type 2 Diabetes market faces significant restraints, including high treatment costs, limited access to advanced therapies, and concerns regarding medication side effects.
Ans: North America is the dominant region in the Type 2 Diabetes market.
Table of contents:
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research & Academic Institutes Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research & Academic Institutes Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends (2023), by Region
5.3 Insulin and Non-Insulin Therapy Adoption Trends (2023-2032)
5.4 Medical Devices for Type 2 Diabetes: Usage & Adoption Trends (2020-2032)
5.5 Disease Progression and Complication Trends (2023-2032)
5.6 Clinical Trials and Pipeline Trends (2023-2032)
5.7 Patient Awareness and Lifestyle Trends (2023-2032)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and Promotional Activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Type 2 Diabetes Market Segmentation, by Drugs Class
7.1 Chapter Overview
7.2 Insulin
7.2.1 Insulin Market Trends Analysis (2020-2032)
7.2.2 Insulin Market Size Estimates and Forecasts to 2032 (USD Million)
7.3 DPP-4 Inhibitors
7.3.1 DPP-4 Inhibitors Market Trends Analysis (2020-2032)
7.3.2 DPP-4 Inhibitors Market Size Estimates and Forecasts to 2032 (USD Million)
7.4 GLP-1 Receptor Agonists
7.4.1 GLP-1 Receptor Agonists Market Trends Analysis (2020-2032)
7.4.2 GLP-1 Receptor Agonists Market Size Estimates and Forecasts to 2032 (USD Million)
7.5 SGLT2 Inhibitors
7.5.1 SGLT2 Inhibitors Market Trends Analysis (2020-2032)
7.5.2 SGLT2 Inhibitors Market Size Estimates and Forecasts to 2032 (USD Million)
7.6 Others
7.6.1 Others Market Trends Analysis (2020-2032)
7.6.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
8. Type 2 Diabetes Market Segmentation, by Route of Administration
8.1 Chapter Overview
8.2 Oral
8.2.1 Oral Market Trends Analysis (2020-2032)
8.2.2 Oral Market Size Estimates and Forecasts to 2032 (USD Million)
8.3 Subcutaneous
8.3.1 Subcutaneous Market Trends Analysis (2020-2032)
8.3.2 Subcutaneous Market Size Estimates and Forecasts to 2032 (USD Million)
8.4 Intravenous
8.4.1 Intravenous Market Trends Analysis (2020-2032)
8.4.2 Intravenous Market Size Estimates and Forecasts to 2032 (USD Million)
9. Type 2 Diabetes Market Segmentation, by Distribution Channel
9.1 Chapter Overview
9.2 Retail Pharmacies
9.2.1 Retail Pharmacies Market Trends Analysis (2020-2032)
9.2.2 Retail Pharmacies Market Size Estimates and Forecasts to 2032 (USD Million)
9.3 Hospital Pharmacies
9.3.1 Hospital Pharmacies Market Trends Analysis (2020-2032)
9.3.2 Hospital Pharmacies Market Size Estimates and Forecasts to 2032 (USD Million)
9.4 Other
9.4.1 Other Market Trends Analysis (2020-2032)
9.4.2 Other Market Size Estimates and Forecasts to 2032 (USD Million)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Type 2 Diabetes Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.2.3 North America Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.2.4 North America Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.2.5 North America Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.2.6 USA
10.2.6.1 USA Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.2.6.2 USA Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.2.6.3 USA Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.2.7 Canada
10.2.7.1 Canada Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.2.7.2 Canada Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.2.7.3 Canada Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.2.8 Mexico
10.2.8.1 Mexico Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.2.8.2 Mexico Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.2.8.3 Mexico Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Type 2 Diabetes Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.1.3 Eastern Europe Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.1.4 Eastern Europe Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.1.5 Eastern Europe Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.1.6 Poland
10.3.1.6.1 Poland Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.1.6.2 Poland Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.1.6.3 Poland Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.1.7 Romania
10.3.1.7.1 Romania Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.1.7.2 Romania Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.1.7.3 Romania Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.1.8.2 Hungary Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.1.8.3 Hungary Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.1.9 turkey
10.3.1.9.1 Turkey Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.1.9.2 Turkey Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.1.9.3 Turkey Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.1.10.2 Rest of Eastern Europe Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.1.10.3 Rest of Eastern Europe Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Type 2 Diabetes Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.2.3 Western Europe Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.2.4 Western Europe Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.2.5 Western Europe Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.6 Germany
10.3.2.6.1 Germany Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.2.6.2 Germany Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.2.6.3 Germany Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.7 France
10.3.2.7.1 France Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.2.7.2 France Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.2.7.3 France Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.8 UK
10.3.2.8.1 UK Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.2.8.2 UK Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.2.8.3 UK Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.9 Italy
10.3.2.9.1 Italy Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.2.9.2 Italy Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.2.9.3 Italy Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.10 Spain
10.3.2.10.1 Spain Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.2.10.2 Spain Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.2.10.3 Spain Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.2.11.2 Netherlands Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.2.11.3 Netherlands Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.2.12.2 Switzerland Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.2.12.3 Switzerland Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.13 Austria
10.3.2.13.1 Austria Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.2.13.2 Austria Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.2.13.3 Austria Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.3.2.14.2 Rest of Western Europe Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.3.2.14.3 Rest of Western Europe Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Type 2 Diabetes Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.4.3 Asia Pacific Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.4.4 Asia Pacific Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.4.5 Asia Pacific Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4.6 China
10.4.6.1 China Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.4.6.2 China Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.4.6.3 China Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4.7 India
10.4.7.1 India Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.4.7.2 India Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.4.7.3 India Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4.8 Japan
10.4.8.1 Japan Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.4.8.2 Japan Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.4.8.3 Japan Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4.9 South Korea
10.4.9.1 South Korea Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.4.9.2 South Korea Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.4.9.3 South Korea Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4.10 Vietnam
10.4.10.1 Vietnam Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.4.10.2 Vietnam Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.4.10.3 Vietnam Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4.11 Singapore
10.4.11.1 Singapore Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.4.11.2 Singapore Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.4.11.3 Singapore Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4.12 Australia
10.4.12.1 Australia Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.4.12.2 Australia Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.4.12.3 Australia Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.4.13.2 Rest of Asia Pacific Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.4.13.3 Rest of Asia Pacific Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Type 2 Diabetes Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.1.3 Middle East Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.5.1.4 Middle East Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.5.1.5 Middle East Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.1.6 UAE
10.5.1.6.1 UAE Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.5.1.6.2 UAE Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.5.1.6.3 UAE Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.5.1.7.2 Egypt Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.5.1.7.3 Egypt Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.5.1.8.2 Saudi Arabia Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.5.1.8.3 Saudi Arabia Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.5.1.9.2 Qatar Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.5.1.9.3 Qatar Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.5.1.10.2 Rest of Middle East Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.5.1.10.3 Rest of Middle East Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Type 2 Diabetes Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.2.3 Africa Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.5.2.4 Africa Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.5.2.5 Africa Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.5.2.6.2 South Africa Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.5.2.6.3 South Africa Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.5.2.7.2 Nigeria Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.5.2.7.3 Nigeria Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.5.2.8.2 Rest of Africa Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.5.2.8.3 Rest of Africa Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Type 2 Diabetes Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.6.3 Latin America Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.6.4 Latin America Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.6.5 Latin America Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.6.6 Brazil
10.6.6.1 Brazil Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.6.6.2 Brazil Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.6.6.3 Brazil Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.6.7 Argentina
10.6.7.1 Argentina Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.6.7.2 Argentina Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.6.7.3 Argentina Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.6.8 Colombia
10.6.8.1 Colombia Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.6.8.2 Colombia Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.6.8.3 Colombia Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Type 2 Diabetes Market Estimates and Forecasts, by Drugs Class (2020-2032) (USD Million)
10.6.9.2 Rest of Latin America Type 2 Diabetes Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Million)
10.6.9.3 Rest of Latin America Type 2 Diabetes Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11. Company Profiles
11.1 Amgen Inc.
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Product / Services Offered
11.1.4 SWOT Analysis
11.2 AstraZeneca PLC
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Product / Services Offered
11.2.4 SWOT Analysis
11.3 Boehringer Ingelheim International GmbH
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Product / Services Offered
11.3.4 SWOT Analysis
11.4 Daiichi Sankyo Co. Ltd
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Product / Services Offered
11.4.4 SWOT Analysis
11.5 Eli Lilly and Company
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Product / Services Offered
11.5.4 SWOT Analysis
11.6 Merck & Co. Inc.
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Product / Services Offered
11.6.4 SWOT Analysis
11.7 Novartis AG
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Product / Services Offered
11.7.4 SWOT Analysis
11.8 Novo Nordisk AS
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Product / Services Offered
11.8.4 SWOT Analysis
11.9 Sanofi SA
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Product / Services Offered
11.9.4 SWOT Analysis
11.10 Takeda Pharmaceutical Co. Ltd
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Product / Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Drug Class
Insulin
DPP-4 Inhibitors
GLP-1 Receptor Agonists
SGLT2 Inhibitors
Others
By Route of Administration
Oral
Subcutaneous
Intravenous
By Distribution Channel
Retail Pharmacies
Hospital Pharmacies
Other
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The Growth hormone deficiency market Size was valued at USD 5.4 billion in 2023 and is expected to reach USD 8.5 billion by 2032 and grow at a CAGR of 5.0% over the forecast period 2024-2032.
The Particle Counter Market Size was valued at USD 223.6 million in 2023 and is expected to reach USD 418.56 million by 2032 and grow at a CAGR of 7.23%.
The Medication Management Market Size was valued at USD 7.08 Billion in 2023 and is expected to reach USD 13.37 Billion by 2032 and grow at a CAGR of 7.66% over the forecast period 2024-2032.
The Medical Device Cleaning Market size was valued at USD 21.74 billion in 2023 and is expected to reach USD 51.96 billion by 2032, growing at a CAGR of 10.22% from 2024-2032.
Lung Cancer Surgery Market was valued at USD 5.4 billion in 2023 and is expected to reach USD 7.9 billion by 2032 and grow at a CAGR of 4.3% from 2024 to 2032.
The Functional Endoscopic Sinus Surgery Market Size was valued at USD 1.01 Billion in 2023, and is expected to reach USD 1.91 Billion by 2032, and grow at a CAGR of 7.66% over the Forecast Period of 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
